LY 297802 (vedaclidine)
3
relevant articles (1 outcomes,
1 trials/studies)
found for this Bio-Agent
Description:
structure given in first source
Also Known As:
vedaclidine; (3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo(2.2.2)octane; LY297802
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
| 1. | Pain (Aches)
11/03/1995
- " A method for determining a selective muscarinic agent, LY297802 (compound I), [(3-(3-1-butylthio)-1,2,5-thiadiazol-4-yl)-1-azabicyclo-2.2.2-octa ne], indicated in the treatment of pain, in rat, rabbit, and monkey plasma is described" 09/01/2000
- " Moreover, the present results suggest that muscarinic receptor agonists such as vedaclidine may be useful in the treatment of persistent pain states that are due at least in part to dysfunction of inhibitory second messenger systems." 09/01/2001
- " The present studies demonstrate that vedaclidine produces antihyperalgesic effects in models involving central sensitization, suggesting that vedaclidine, and potentially other muscarinic receptor agonists, may have clinical utility in the management of pain states involving central sensitization, such as neuropathic and inflammatory pain states."
Get all the results and reference details, order at left...
|
| 2. | Hyperalgesia
|
| 2 Diseases
and
3
more articles analyzed in the Research Interface, order at left...
|
Related Drugs and Biologics